Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More
Close

Rockland Immunochemicals, Inc.

We advance life science to foster a better world

Rockland Immunochemicals, Inc. Awarded SBIR Funding to Develop Antibody-Based Point of Care Device for the Diagnosis of Sickle Cell Disease

Limerick, PA. September 8th, 2014 – Rockland Immunochemicals, Inc. (Rockland) announced today the award of a $224,473 Small Business Innovation Research (SBIR) grant from the NIH National Heart Lung and Blood Institute (NHLBI) to develop an antibody-based point of care device for the diagnosis of Sickle Cell Disease (SCD), a mutation that is carried in approximately 7% of the world’s population. Rockland secured the award by demonstrating the technology and processes it deploys to develop and to produce leading edge life science tools for basic and clinical research focused on functional genomics and drug discovery markets.

Sickle cell anemia (SCA) is the most common form of SCD which is the fifth most common genetic disorder in the world. SCD occurs when red blood cells are unable to carry adequate oxygen throughout the body due to their deformation. SCD is extremely painful in those affected. Early detection of SCD can help reduce the risk of life-threatening infections and increase the odds for survival. Also, diagnosis enables treatment with pain medication that can ease most symptoms, including abdominal, chest and bone pain, fatigue, shortness of breath, accelerated heart rate, delayed puberty, stunted growth, fever, and leg ulcers.

Currently, there are no simple and cost effective screening tests that can differentiate patients with the sickle cell trait (HbAS) from sickle cell disease conditions (HbSS, HbSC and HbS β-thalassemias). “Rockland’s antibody technology platform will help to overcome these barriers tremendously. We will create novel hemoglobin isoform-specific antibodies and configure a lateral flow point-of-care assay.” said Dr. Carl Ascoli, Rockland’s Chief Science Officer. “As a result of this project, the antibody-based lateral flow point-of-care device will allow rapid and inexpensive diagnosis of Sickle Cell Disease in infants and young children in industrialized and low-income and low-resource settings.”

About Rockland Immunochemicals, Inc.

Rockland Immunochemicals, Inc. supports the academic, biopharma, and diagnostic industries with antibodies and antibody based tools used in basic research, assay development, and preclinical studies. With facilities in Pennsylvania for over 50 years, Rockland manufactures products ideally suited for integration into critical assays such as western blotting, immunohistochemistry (IHC), immunofluorescence microscopy (IF), ELISA and flow cytometry. Additional information about Rockland’s life science tools and services can be found on Rockland’s website at www.rockland-inc.com.

For additional information regarding this announcement, please contact:

Dana Dever
Marketing, Rockland Immunochemicals, Inc.
Phone: 484.791.3823
Email: dana.dever@rockland-inc.com